Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma: CSCO and ASCO Joint Guideline
In brief
Guideline favors chemotherapy plus immunotherapy first for recurrent nasopharyngeal cancer
For medically fit patients with recurrent or metastatic nasopharyngeal cancer, the guideline recommends platinum-based chemotherapy plus a PD-1 inhibitor, followed by maintenance immunotherapy for up to 2 years. Chemotherapy alone is an option when immunotherapy is unsuitable; selected responders may receive maintenance chemotherapy or radiation, and isolated recurrences may be treated locally. Choices depend on prior treatment, patient fitness, access, and preferences.
- Journal
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology (Q1)
- Published
- 10 November 2026
- Study design
- Practice guideline / consensus
- Evidence level
- Level 1, High (CEBM 1c)
- Authors
- Wei Jiang, Nofisat Ismaila, Melvin Lk Chua, Robert Haddad, Quynh-Thu Le, A Dimitrios Colevas, et al.
- PMID
- 43008245
- DOI
- 10.1200/JCO-26-02650
Why clinicians should know about it
- Picked for Radiation Oncology (top studies of the week, 15 November 2026): Guideline addresses NPC re-irradiation and locoregional consolidation
Abstract
PURPOSE: To provide evidence-based recommendations on first- and subsequent-line systemic therapy, maintenance therapy, locoregional consolidation, and salvage local therapy for patients with recurrent and/or metastatic nasopharyngeal carcinoma (NPC). METHODS: A multidisciplinary Expert Panel convened by CSCO and ASCO reviewed evidence from randomized trials, meta-analyses, systematic reviews, prospective and retrospective studies, and clinical experience. The guideline was informed by a systematic literature review and consensus-based interpretation of efficacy, safety, feasibility, and patient-centered outcomes across scenarios. Outcomes included overall and progression-free survival, response and disease control rates, toxicity, and quality of life. RESULTS: Evidence supports platinum-based chemotherapy plus a programmed cell death protein 1 (PD-1) inhibitor as preferred first-line therapy for medically fit patients. Evidence also supports maintenance strategies after disease control, while treatment selection depends on prior treatment, disease extent, patient fitness, resource availability, and preferences. Selected responders may receive locoregional consolidation radiotherapy or oral maintenance chemotherapy. For isolated locoregional recurrence amenable to local therapy, options include salvage surgery and re-irradiation. RECOMMENDATIONS: Chemotherapy plus a PD-1 inhibitor, followed by maintenance PD-1 inhibition for up to 2 years, should be offered first-line to appropriate patients with recurrent and/or metastatic NPC. Chemotherapy alone may be offered when immunotherapy is unsuitable or declined. Selected patients responding to first-line chemotherapy may receive oral maintenance chemotherapy or locoregional consolidation intensity-modulated radiotherapy. Salvage surgery or re-irradiation is recommended for appropriately selected patients with isolated locoregional recurrence. Subsequent-line options include chemotherapy, PD-1 inhibitors, and antibody-drug conjugates. Treatment should be individualized according to disease setting, prior therapy, expected toxicities, availability, local drug approvals, and patient preferences. Early supportive and specialist interdisciplinary palliative care, where available, should accompany active anticancer treatment for advanced, incurable disease.Additional information is available at www.ascopubs.org/topics/asco-guidelines/head-neck-cancer.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.